TY - JOUR T1 - Growth attenuation therapy: practice and perspectives of paediatric endocrinologists JF - Archives of Disease in Childhood JO - Arch Dis Child DO - 10.1136/archdischild-2015-309130 SP - archdischild-2015-309130 AU - Allison J Pollock AU - Norman Fost AU - David B Allen Y1 - 2015/07/22 UR - http://adc.bmj.com/content/early/2015/07/22/archdischild-2015-309130.abstract N2 - For non-ambulatory children with severe physical and cognitive disabilities (SPCD), being lifted and transported become more challenging with increasing size. Reduction in length and overall size for select children with SPCD can be accomplished by growth attenuation therapy (GAT), which reduces linear growth by administering hormones (eg, oestrogen) that accelerate epiphyseal closure. There are no reliable data describing attitudes and practices of paediatric endocrinologists regarding GAT for children with SPCD.In collaboration with the Pediatric Endocrine Society (PES), an anonymous questionnaire about GAT was emailed to PES physician members (n=1100, 92% from the USA). Responses were stripped of identifiable information. Consent was implied by responding. The study received institutional review board exemption status at the University of Wisconsin–Madison.Two hundred and eighty-four PES members responded … ER -